Pyxis肿瘤学的主要药物显示,早期头部和颈部癌的试验取得了有希望的成果。 Pyxis Oncology's lead drug shows promising results in early trials for head and neck cancer.

Pyxis肿瘤学是一家生物技术公司,正在优先考虑其主要药物PYX-201,这是针对特定肿瘤成分的创新的抗体药物配方。 Pyxis Oncology, a biotech firm, is prioritizing its lead drug PYX-201, an innovative antibody-drug conjugate targeting a specific tumor component. 第一阶段初步数据显示头部和颈部癌症患者的回复率为50%。 Preliminary Phase 1 data showed a 50% response rate in head and neck cancer patients. 该公司的当前资金预计将支持PYX-201试验进入2026年中期,计划进行独立治疗和混合治疗。 The company's current funds are projected to support PYX-201 trials into mid-2026, with plans for both standalone and combination treatments.